JPWO2022155482A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022155482A5
JPWO2022155482A5 JP2023542960A JP2023542960A JPWO2022155482A5 JP WO2022155482 A5 JPWO2022155482 A5 JP WO2022155482A5 JP 2023542960 A JP2023542960 A JP 2023542960A JP 2023542960 A JP2023542960 A JP 2023542960A JP WO2022155482 A5 JPWO2022155482 A5 JP WO2022155482A5
Authority
JP
Japan
Prior art keywords
seq
aav vector
nucleic acid
capsid protein
recombinant aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023542960A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024503091A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/012542 external-priority patent/WO2022155482A1/en
Publication of JP2024503091A publication Critical patent/JP2024503091A/ja
Publication of JPWO2022155482A5 publication Critical patent/JPWO2022155482A5/ja
Pending legal-status Critical Current

Links

JP2023542960A 2021-01-14 2022-01-14 T細胞を標的とするaavベクター Pending JP2024503091A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163137497P 2021-01-14 2021-01-14
US63/137,497 2021-01-14
PCT/US2022/012542 WO2022155482A1 (en) 2021-01-14 2022-01-14 Aav vectors targeting t-cells

Publications (2)

Publication Number Publication Date
JP2024503091A JP2024503091A (ja) 2024-01-24
JPWO2022155482A5 true JPWO2022155482A5 (enExample) 2025-01-22

Family

ID=81328090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023542960A Pending JP2024503091A (ja) 2021-01-14 2022-01-14 T細胞を標的とするaavベクター

Country Status (10)

Country Link
US (1) US20240123085A1 (enExample)
EP (1) EP4277920A1 (enExample)
JP (1) JP2024503091A (enExample)
KR (1) KR20230135093A (enExample)
CN (1) CN117203222A (enExample)
AR (1) AR124651A1 (enExample)
AU (1) AU2022208037A1 (enExample)
CA (1) CA3204794A1 (enExample)
TW (1) TW202242124A (enExample)
WO (1) WO2022155482A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2024004217A (es) 2021-10-08 2024-06-26 Dyno Therapeutics Inc Variantes de cápside y métodos de uso de estas.
WO2024124019A2 (en) * 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2025179007A1 (en) * 2024-02-21 2025-08-28 The Regents Of The University Of California Adeno-associated virus compositions and methods of use thereof for human cells

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0322417A1 (en) 1986-09-08 1989-07-05 Applied Biotechnology, Inc. Empty viral capsid vaccines
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
EP0442926A1 (en) 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
US5916563A (en) 1988-11-14 1999-06-29 United States Of America Parvovirus protein presenting capsids
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ES2026826A6 (es) 1991-03-26 1992-05-01 Ercros Sa Procedimiento para la produccion de una vacuna subunidad contra el parvovirus canino y otros virus relacionados.
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869248A (en) 1994-03-07 1999-02-09 Yale University Targeted cleavage of RNA using ribonuclease P targeting and cleavage sequences
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
US6040183A (en) 1995-06-07 2000-03-21 University Of North Carloina At Chapel Hill Helper virus-free AAV production
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6083702A (en) 1995-12-15 2000-07-04 Intronn Holdings Llc Methods and compositions for use in spliceosome mediated RNA trans-splicing
ES2279531T3 (es) 1995-12-15 2007-08-16 Intronn, Inc. Moleculas terapeuticas generadas por corte y empalme en trans.
EP0932694A2 (en) 1996-09-11 1999-08-04 THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Aav4 vector and uses thereof
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
DE69939169D1 (de) 1998-05-28 2008-09-04 Us Gov Health & Human Serv Aav5 vektoren und deren verwendung
CA2347129A1 (en) 1998-09-22 2000-03-30 University Of Florida Methods for large-scale production of recombinant aav vectors
PT1127150E (pt) 1998-11-05 2007-08-22 Univ Pennsylvania ''sequências de ácido nucleico do vírus adeno associado do serotipo 1, vectores e células hospedeiras que as contêm''
ATE454445T1 (de) 1998-11-10 2010-01-15 Univ North Carolina Virusvektoren und verfahren für ihre herstellung und verabreichung.
US7314912B1 (en) 1999-06-21 2008-01-01 Medigene Aktiengesellschaft AAv scleroprotein, production and use thereof
NZ522840A (en) 2000-06-01 2004-12-24 Univ North Carolina A parvovirus vector that carries a duplexed genome resulting in co-packaging of strands of plus and minus polarity tethered together
AU2001268149B2 (en) 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
US6623729B2 (en) 2001-07-09 2003-09-23 Korea Advanced Institute Of Science And Technology Process for preparing sustained release micelle employing conjugate of anticancer drug and biodegradable polymer
WO2003093295A2 (en) 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill Secretion signal vectors
ITRM20020253A1 (it) 2002-05-08 2003-11-10 Univ Roma Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
JP4346526B2 (ja) 2004-08-31 2009-10-21 株式会社東芝 半導体集積回路装置
US9114148B2 (en) 2004-09-09 2015-08-25 University Of Cincinnati Modulating phosphatase activity in cardiac cells
US7892809B2 (en) 2004-12-15 2011-02-22 The University Of North Carolina At Chapel Hill Chimeric vectors
US20100196335A1 (en) 2005-04-29 2010-08-05 Samulski Richard J Methods and Compositions for Regulated Expressions of Nucleic Acid at Post-Transcriptional Level
WO2006119432A2 (en) * 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP1994043A4 (en) 2006-02-10 2009-05-20 Univ Cincinnati PHOSPHATASE INHIBITOR PROTEIN 1 AS A REGULATOR OF HEART FUNCTION
WO2008088895A2 (en) 2007-01-18 2008-07-24 University Of Missouri-Columbia Synthetic mini/micro-dystrophin genes to restore nnos to the sarcolemma
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
EP2940131B1 (en) * 2012-12-25 2019-02-20 Takara Bio Inc. Aav variant
CN105163764B (zh) 2013-03-15 2019-11-12 北卡罗来纳-查佩尔山大学 双重聚糖结合aav载体的方法和组合物
CA2907799A1 (en) * 2013-05-31 2014-12-04 The Regents Of The University Of California Adeno-associated virus variants and methods of use thereof
ES2952525T3 (es) * 2016-09-08 2023-11-02 2Seventy Bio Inc Variantes de endonucleasa homing PD-1, composiciones y métodos de uso
EP3589277A4 (en) * 2017-02-28 2020-08-26 Adverum Biotechnologies, Inc. MODIFIED AVA CAPSIDES AND USE OF THESE LATEST
JP7425738B2 (ja) 2018-04-03 2024-01-31 ギンコ バイオワークス インコーポレイテッド 眼組織を標的とするウイルスベクター
MX2020010464A (es) 2018-04-03 2021-01-29 Vectores de virus que evitan anticuerpos.
US12091435B2 (en) 2018-04-03 2024-09-17 Ginkgo Bioworks, Inc. Antibody-evading virus vectors

Similar Documents

Publication Publication Date Title
FI4211231T3 (fi) Peptidimodifioitu aav-kapsidi
JP2023179436A5 (enExample)
JP2024178382A5 (enExample)
JP2020510428A5 (enExample)
JP2020508685A5 (enExample)
JPWO2019193119A5 (enExample)
JP2010516758A5 (enExample)
RU2018129159A (ru) Рекомбинантные aav векторы, экспрессирующие остеопротективные гены, включая has2 и лубрицин, пригодные при лечении остеоартрита и сходных заболеваний суставов у млекопитающих
JPWO2020218419A5 (enExample)
US20240002462A1 (en) Treatment of neuropathy with igf-1-encoding dna constructs and hgf-encoding dna constructs
JPWO2021116462A5 (enExample)
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
FI4536686T3 (fi) Lihaksen parannetun transduktiotehokkuuden omaava peptidimodifioitu aav-kapsidi
JP2003503355A5 (enExample)
JP2018537089A5 (enExample)
JPWO2020205889A5 (enExample)
JP2024056832A5 (enExample)
CN114276419A (zh) 肌肉高亲和性的新型腺相关病毒衣壳蛋白及其应用
JPWO2022155482A5 (enExample)
CN115806984A (zh) 环状rna及载体和载体的应用
JPWO2020030927A5 (enExample)
JPWO2022015715A5 (enExample)
JP2008503569A5 (enExample)
RU2021133906A (ru) Мутант aav, обладающий способностью нацеливаться на головной мозг
JPWO2020219726A5 (enExample)